HYDERABAD: The US Food and Drug Administration has put on hold the phase 2/3 clinical trials of Bharat Biotech’s Covid-19 vaccine Covaxin in the US.
According to a press release by Ocugen Inc, Bharat Biotech’s partner for US and Canada for Covaxin, the FDA’s decision was based on the US firm’s decision to voluntarily implement a temporary pause in dosing participants of the jab following the World Health Organisation’s observations on Covaxin manufacturing plants in India.